ArticleBMC infectious diseases2014
Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 129 citations in OpenAlex.
- Molecular and Epidemiological Surveillance of Sporothrix spp. in Cats and Dogs from Southern Brazil.Mycopathologia · 2026Article
- Article
- Establishment of epidemiological cutoff values for clinically relevantAntimicrobial agents and chemotherapy · 2026Article
- Unusual Sporotrichosis: A New Concept Proposal on the Unexpected Faces ofJournal of fungi (Basel, Switzerland) · 2026Review
- Emergence of difficult-to-treat lymphocutaneous sporotrichosis? Analysis based on three cases with high and low MIC Sporothrix brasiliensis isolates.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Current Insights intoJournal of fungi (Basel, Switzerland) · 2025Article
- Disasters pile up on the rubbing heel:Emerging microbes & infections · 2024Article
- Milteforan, a promising veterinary commercial product against feline sporotrichosis.Microbiology spectrum · 2024Article
- Novel Insights into Sporotrichosis and Diabetes.Journal of fungi (Basel, Switzerland) · 2024Review
- What are the 100 most cited fungal genera?Studies in mycology · 2024Article
- In vitro activity of the anthelmintic drug niclosamide against Sporothrix spp. strains with distinct genetic and antifungal susceptibility backgrounds.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Bimodal distribution of azole susceptibility inAntimicrobial agents and chemotherapy · 2024Article
- Milteforan, a promising veterinary commercial product against feline sporotrichosis.bioRxiv : the preprint server for biology · 2024Article
- Cutaneous disseminated sporotrichosis associated with diabetes: A case report and literature review.PLoS neglected tropical diseases · 2023Review
- Phenotypic and Genotypic Characterization and Antifungal Susceptibility ofJournal of fungi (Basel, Switzerland) · 2023Article
- Current Progress inJournal of fungi (Basel, Switzerland) · 2023Review
- High-Throughput Microsatellite Markers Development for Genetic Characterization of EmergingJournal of fungi (Basel, Switzerland) · 2023Article
- Meningeal Sporotrichosis Due toJournal of fungi (Basel, Switzerland) · 2022Article
- Trends in Molecular Diagnostics and Genotyping Tools Applied for EmergingJournal of fungi (Basel, Switzerland) · 2022Review
- Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends.Journal of fungi (Basel, Switzerland) · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSporotrichosis is a chronic subcutaneous mycosis of humans and animals, which is typically acquired by traumatic inoculation of plant material contaminated with Sporothrix propagules, or via animals, mainly felines. Sporothrix infections notably occur in outbreaks, with large epidemics currently taking place in southeastern Brazil and northeastern China. Pathogenic species include Sporothrix brasiliensis, Sporothrix schenckii s. str., Sporothrix globosa, and Sporothrix luriei, which exhibit differing geographical distribution, virulence, and resistance to antifungals. The phylogenetically remote species Sporothrix mexicana also shows a mild pathogenic potential.
methodsWe assessed a genetically diverse panel of 68 strains. Susceptibility profiles of medically important Sporothrix species were evaluated by measuring the MICs and MFCs for amphotericin B (AMB), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), posaconazole (PCZ), flucytosine (5FC), and caspofungin (CAS). Haplotype networks were constructed to reveal interspecific divergences within clinical Sporothrix species to evaluate genetically deviant isolates.
resultsITC and PCZ were moderately effective against S. brasiliensis (MIC90 = 2 and 2 μg/mL, respectively) and S. schenckii (MIC90 = 4 and 2 μg/mL, respectively). PCZ also showed low MICs against the rare species S. mexicana. 5FC, CAS, and FLC showed no antifungal activity against any Sporothrix species. The minimum fungicidal concentration ranged from 2 to >16 μg/mL for AMB against S. brasiliensis and S. schenckii, while the MFC90 was >16 μg/mL for ITC, VRC, and PCZ.
conclusionSporothrix species in general showed high degrees of resistance against antifungals. Evaluating a genetically diverse panel of strains revealed evidence of multidrug resistant phenotypes, underlining the need for molecular identification of etiologic agents to predict therapeutic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.